Wellgistics Health, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. The company is headquartered in Tampa, Florida. The company went IPO on 2025-02-21. The company focuses on specialty medications and a community-based model offering home delivery services to patients. The company is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.
最新の財務諸表(Form-10K)によると、Wellgistics Health Incの総資産は$57で、純損失は$-6です。
WGRXの主要な財務比率は何ですか?
Wellgistics Health Incの流動比率は1.14、純利益率は-33.33、1株当たり売上高は$0.38です。
Wellgistics Health Incの収益はセグメントまたは地域別にどのように分けられていますか?
Wellgistics Health Inc の最大収益セグメントは Investment and Related Activities で、最新の利益発表における収益は 341,995,000 です。地域別に見ると、United States が Wellgistics Health Inc の主要市場であり、収益は 341,995,000 です。